SCHEMBL537790

SCHEMBL537790

COc1cc2c(cc1OC)C(CCN)C2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 1/20 0.43
MTNR1A P48039 1/20 0.43
MTNR1B P49286 1/20 0.43
ABCB1 P08183 1/20 0.41
KCNN2 Q9H2S1 4/20 0.41
KCNN3 Q9UGI6 4/20 0.41
KCNN1 Q92952 2/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
KDM4E B2RXH2 1/20 0.40
ATM Q13315 1/20 0.40
CHRM2 P08172 1/20 0.39
HTR1A P08908 1/20 0.39
SLC6A4 P31645 1/20 0.39
DRD3 P35462 1/20 0.39
KCNH2 Q12809 1/20 0.39
HCN4 Q9Y3Q4 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3143094 1.00 NQO2 (0.43) NQO2MTNR1AMTNR1BABCB1KCNN2
SCHEMBL3162728 1.00 NQO2 (0.43) NQO2MTNR1AMTNR1BABCB1KCNN2
Hydrochloric Acid SCHEMBL9427134 0.98 KCNN2 (0.42) NQO2MTNR1AMTNR1BABCB1KCNN2
SCHEMBL4244596 0.90 ABCB1 (0.42) NQO2MTNR1AMTNR1BABCB1KCNN2
SCHEMBL15158492 0.89 NQO2 (0.43) NQO2MTNR1AMTNR1BCYP3A4CHRM2
SCHEMBL4746611 0.89 TAAR1 (0.42) NQO2MTNR1AMTNR1BCHRM2HTR1A
SCHEMBL4746590 0.89 TAAR1 (0.42) NQO2MTNR1AMTNR1BCHRM2HTR1A
SCHEMBL31549 0.86 CYP3A4 (0.43) NQO2MTNR1AMTNR1BCYP3A4MAPT
SCHEMBL383341 0.86 CYP3A4 (0.43) NQO2MTNR1AMTNR1BCYP3A4MAPT
SCHEMBL7436614 0.86 CYP3A4 (0.43) NQO2MTNR1AMTNR1BCYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8927758-B2 Process for the resolution of enantiomers of (3,4 dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl)nitrile and application in the synthesis of ivabradine LES LABORATORIES SERVIER (FR) 2015-01-06 US disclosed
US-8778930-B2 Process for the resolution of enantiomers of (3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl)nitrile and application in the synthesis of ivabradine LES LABORATORIES SERVIER (FR) 2014-07-15 US disclosed
US-20130211070-A1 NEW PROCESS FOR THE RESOLUTION OF ENANTIOMERS OF (3,4 DIMETHOXY-BICYCLO[4.2.0]OCTA-1,3,5-TRIEN-7-YL)NITRILE AND APPLICATION IN THE SYNTHESIS OF IVABRADINE LES LABORATOIRES SERVIER (FR) 2013-08-15 US disclosed
US-20130204032-A1 NEW PROCESS FOR THE RESOLUTION OF ENANTIOMERS OF (3,4 DIMETHOXY-BICYCLO[4.2.0]OCTA-1,3,5-TRIEN-7-YL)NITRILE AND APPLICATION IN THE SYNTHESIS OF IVABRADINE LES LABORATOIRES SERVIER (FR) 2013-08-08 US disclosed
EP-2460797-A2 Process for preparation of ivabradine hydrochloride Cadila Healthcare Limited (IN) 2012-06-06 EP disclosed
US-8119794-B2 Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid LES LABORATOIRES SERVIER (FR) 2012-02-21 US disclosed
EP-2097383-B1 Process for preparation of ivabradine hydrochloride CADILA HEALTHCARE LTD (IN) 2012-02-08 EP disclosed
US-8110701-B2 Process for the preparation of functionalised benzocyclobutenes, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid LES LABORATOIRES SERVIER (FR) 2012-02-07 US disclosed
US-8101747-B2 Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid LES LABORATOIRES SERVIER (FR) 2012-01-24 US disclosed
US-8097720-B2 Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid Les Laboratories Server (FR) 2012-01-17 US disclosed
US-20100249398-A1 Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid LES LABORATOIRES SERVIER (FR) 2010-09-30 US disclosed
US-20100160628-A1 Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid LES LABORATOIRES SERVIER (FR) 2010-06-24 US disclosed
EP-2036892-B1 1,2,4,5-tetrahydro-3H-benzazepine derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2010-03-10 EP disclosed
US-20100056778-A1 Process for the resolution of enantiomers of (3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl) nitrile and application in the synthesis of ivabradine LES LABORATOIRES SERVIER (FR) 2010-03-04 US disclosed
US-20100016580-A1 Process for the preparation of functionalised benzocyclobutenes, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid LES LABORATOIRES SERVIER (FR) 2010-01-21 US disclosed
EP-2097383-A2 PROCESS FOR PREPARATION OF IVABRADINE HYDROCHLORIDE Cadila Healthcare Limited (IN) 2009-09-09 EP disclosed
WO-2009066041-A2 DERIVATIVES OF 1,2,4,5-TETRAHYDRO-3H-BENZAZEPINES, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2009-05-28 WO disclosed
EP-2036892-A1 1,2,4,5-tetrahydro-3H-benzazepine derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2009-03-18 EP disclosed
US-20090069296-A1 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2009-03-12 US disclosed
WO-2008065681-A2 PROCESS FOR PREPARATION OF IVABRADINE HYDROCHLORIDE CADILA HEALTHCARE LIMITED (IN) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130211070-A1 NEW PROCESS FOR THE RESOLUTION OF ENANTIOMERS OF (3,4 DIMETHOXY-BICYCLO[4.2.0]OCTA-1,3,5-TRIEN-7-YL)NITRILE AND APPLICATION IN THE SYNTHESIS OF IVABRADINE HCN4, NISCH, SCN5A NQO2 2169/4885MTNR1A 2118/4885MTNR1B 1871/4885
US-20130204032-A1 NEW PROCESS FOR THE RESOLUTION OF ENANTIOMERS OF (3,4 DIMETHOXY-BICYCLO[4.2.0]OCTA-1,3,5-TRIEN-7-YL)NITRILE AND APPLICATION IN THE SYNTHESIS OF IVABRADINE HCN4, NISCH, SCN5A NQO2 2169/4885MTNR1A 2118/4885MTNR1B 1871/4885
US-20090069296-A1 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them OXER1, NR1H3, OXSR1 NQO2 1600/4885MTNR1A 60/4885MTNR1B 65/4885
US-20100249398-A1 Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid CYP4F2, CYP2F1, CYP2D6 NQO2 553/4885MTNR1A 2929/4885MTNR1B 2008/4885
US-20100016580-A1 Process for the preparation of functionalised benzocyclobutenes, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid BDKRB2, HRH2, C1R NQO2 1170/4885MTNR1A 1951/4885MTNR1B 1781/4885
US-20100056778-A1 Process for the resolution of enantiomers of (3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl) nitrile and application in the synthesis of ivabradine HCN4, NISCH, SCN5A NQO2 1986/4885MTNR1A 1886/4885MTNR1B 1651/4885
US-20100160628-A1 Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid CYP4F2, CYP2F1, CYP2D6 NQO2 553/4885MTNR1A 2929/4885MTNR1B 2008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.